Many of our members are asking if now is the time to sell Eli Lilly, especially with the stock up 101% since our recommendation last year. My answer: definitely not. Eli Lilly is performing like the Nvidia of Big Pharma.
Here’s why:
Alzheimer's Drug Approval: On June 10th, the FDA unanimously approved their new Alzheimer's drug, expected to dominate the treatment market by 2030.
Thyroid Cancer Drug: They’re also on the brink of FDA approval for a thyroid cancer drug that will be available even for pediatric patients.
GLP-1 Weight Loss Drugs: Their weight loss drugs are taking the world by storm, which was the initial reason for our recommendation.
Eli Lilly is on an incredible run, firing on all cylinders. With advancements in treating Alzheimer's, weight loss, and cancer, I believe they could be the first trillion-dollar drug company.
We've seen tremendous success with our weight loss drug recommendations, including Eli Lilly, Novo Nordisk, Viking, and Altimmune. However, the market is evolving, and new companies are exploring innovative approaches.
We’re in a transitional phase, uncertain about the next breakthrough. For now, hold your Eli Lilly and Novo stocks. If Viking and Altimmune become more attractive, I'll keep you updated. Let’s watch this fascinating market evolution together.
🔔 Subscribe and stay tuned for more insights on the pharma market. Have a great day!
✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼
/ @behindthemarkets
✅ VISIT OUR WEBSITE 👇🏼👇🏼
behindthemarke...
4 окт 2024
